Zepbound for Sleep Apnea: The First FDA-Approved OSA Medication
Zepbound is the only prescription drug the FDA has ever approved to treat obstructive sleep apnea. In the SURMOUNT-OSA trials it cut sleep apnea severity by up to nearly two-thirds. Here is what the data shows, whether it replaces CPAP, and how to use this indication to unlock insurance coverage.
Last updated: August 3, 2026
Quick Answer
Zepbound (tirzepatide) is the first and only prescription medicine FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Before this approval, the only treatments were mechanical - CPAP machines, oral appliances, positional therapy, or surgery. No drug had ever been approved for the condition.
In the Phase 3 SURMOUNT-OSA program, tirzepatide reduced sleep apnea severity by up to nearly two-thirds, measured as a significant reduction in the apnea-hypopnea index (AHI). It also reduced body weight, hypoxic burden, hsCRP (an inflammation marker), and systolic blood pressure, while improving sleep-related patient-reported outcomes.
The practical angle most people miss: this indication can open an insurance coverage pathway that a pure obesity claim does not. If you have been denied Zepbound for weight loss and have diagnosed moderate-to-severe OSA, that is worth raising with your prescriber.
What the FDA Actually Approved
The FDA approved Zepbound (tirzepatide) for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. Every element of that phrasing matters:
- Moderate-to-severe - not mild OSA. Severity is determined by your sleep study.
- Obstructive sleep apnea - not central sleep apnea, which has a different mechanism entirely.
- In adults with obesity - the approval is specifically for OSA occurring alongside obesity, not OSA from other causes.
This was a genuine first. Zepbound had already been approved in November 2023 for adults with obesity or overweight with weight-related medical problems. The OSA indication came later, making it the first and only prescription medicine approved for moderate-to-severe obstructive sleep apnea. The American Academy of Sleep Medicine characterized the approval as a positive development for a condition that had never had a pharmacological option.
Why this is a bigger deal than it sounds. Obstructive sleep apnea affects a large share of adults with obesity, and it is dramatically underdiagnosed. Untreated OSA is associated with hypertension, cardiovascular disease, type 2 diabetes, daytime impairment, and accident risk. CPAP works well when used - but real-world adherence is notoriously poor, with many patients abandoning the device. A treatment that works while you sleep without wearing anything addresses the adherence problem directly.
Why Obesity and Sleep Apnea Are Linked
Understanding the mechanism explains why a weight loss drug treats a breathing disorder.
Obstructive sleep apnea occurs when the upper airway repeatedly collapses or narrows during sleep, interrupting breathing. Each interruption triggers a brief arousal as your body fights to restore airflow. You may not remember waking, but the fragmentation destroys sleep quality and repeatedly drops your blood oxygen.
Excess weight contributes through several distinct mechanisms:
- Fat deposition around the airway. Adipose tissue in the neck and around the pharynx physically narrows the airway and makes it more collapsible.
- Tongue fat. Fat within the tongue itself increases its volume, pushing it back into the airway when you lie down.
- Reduced lung volume. Abdominal and chest wall fat reduces functional residual capacity, which mechanically reduces the tension holding the upper airway open.
- Systemic inflammation. Obesity-associated inflammation may affect the muscles that maintain airway patency.
Because these are all weight-dependent, substantial weight loss addresses the underlying anatomy rather than compensating for it. That is the fundamental difference between this drug and CPAP: CPAP splints the airway open every night; weight loss changes why it collapses in the first place.
SURMOUNT-OSA Trial Results
The approval rests on SURMOUNT-OSA, a Phase 3 program published in the New England Journal of Medicine. It evaluated tirzepatide in adults with moderate-to-severe obstructive sleep apnea and obesity, across two studies: one in participants not using PAP therapy, and one in participants who were.
| Outcome Measured | Effect of Tirzepatide |
|---|---|
| Sleep apnea severity (AHI) | Reduced by up to nearly two-thirds |
| Body weight | Significantly reduced |
| Hypoxic burden | Reduced - less oxygen deprivation overnight |
| hsCRP (inflammation marker) | Reduced |
| Systolic blood pressure | Reduced |
| Sleep-related patient-reported outcomes | Improved |
At one year, tirzepatide was associated with significant reductions in AHI, OSA-related nocturnal hypoxia, and overall OSA severity compared with placebo. Secondary analyses published subsequently also reported greater improvement in cardiometabolic risk factors than placebo across both studies.
The breadth of the results is what makes this compelling. Reducing AHI alone would be a narrow win. Reducing AHI and nocturnal oxygen deprivation and systolic blood pressure and inflammation, while improving how patients actually report feeling, addresses the full cluster of harm that untreated OSA causes. Sleep apnea is dangerous largely because of its cardiovascular downstream effects, and those markers moved in the right direction.
Research has also begun identifying which patients respond best to tirzepatide for OSA, which suggests treatment selection will become more targeted as the evidence base grows.
Understanding AHI: What the Numbers Mean
The apnea-hypopnea index counts how many times per hour your breathing stops (apnea) or becomes significantly shallow (hypopnea) during sleep. It is the primary measure used to diagnose and grade OSA.
| AHI (events per hour) | Classification | Zepbound Indication? |
|---|---|---|
| Fewer than 5 | Normal | No |
| 5 to 14 | Mild OSA | No - approval is moderate-to-severe |
| 15 to 29 | Moderate OSA | Yes, with obesity |
| 30 or more | Severe OSA | Yes, with obesity |
This is why a documented sleep study is essential. You cannot self-diagnose into this indication, and insurers will require the objective AHI number. If you suspect you have sleep apnea but have never been tested, getting a sleep study is the necessary first step - and it is worth doing regardless of whether you pursue medication.
Reducing severity by up to nearly two-thirds means someone entering at severe OSA could plausibly move into the mild range. That is a clinically meaningful shift in category, not a marginal improvement.
Does It Replace CPAP?
This is the question everyone asks, and the honest answer is: not automatically, and not on your own initiative.
| Factor | CPAP | Zepbound |
|---|---|---|
| Mechanism | Splints the airway open with air pressure | Reduces the fat that narrows the airway |
| Speed of effect | Immediate - first night | Gradual - follows weight loss over months |
| Effectiveness when used | Very high | Reduced severity up to nearly two-thirds |
| Real-world adherence | Often poor | Weekly injection - generally easier |
| Addresses root cause | No - manages the symptom nightly | Partially - reduces the anatomical driver |
| If you stop | OSA returns that night | Returns as weight is regained |
Do not stop using your CPAP because you started Zepbound. Weight loss on a GLP-1 is gradual - meaningful reduction takes months. Your airway does not change the week you start the medication. Stopping CPAP prematurely means going back to untreated OSA during the entire titration period, with all its cardiovascular and daytime risk.
Any decision to reduce or discontinue PAP therapy must be made by your sleep physician, and should be based on a repeat sleep study documenting that your AHI has actually improved. Notably, SURMOUNT-OSA included a study arm of participants who were using PAP therapy - the two are not mutually exclusive, and using both is a legitimate approach.
The realistic framing: Zepbound is a treatment that may reduce your OSA severity enough to change your therapy over time. It is not an overnight replacement for a device that works from the first night.
Who Qualifies for This Indication
To be prescribed Zepbound specifically for OSA, you generally need to meet the approved criteria:
- An adult - the indication is for adults.
- Diagnosed moderate-to-severe obstructive sleep apnea, documented by a sleep study with an AHI of 15 or higher.
- Obesity - the approval is for OSA occurring in adults with obesity.
- No contraindications to tirzepatide, including a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
You will not qualify under this indication if you have mild OSA, central sleep apnea rather than obstructive, or OSA without obesity. Those are all real conditions that need treatment - just not through this particular approval.
If you have never had a sleep study, start there. OSA is dramatically underdiagnosed, particularly in people who attribute their symptoms to being overweight, stressed, or simply tired. Common signs: loud snoring, witnessed pauses in breathing, waking gasping, morning headaches, and daytime sleepiness despite adequate time in bed. Home sleep apnea tests have made testing far more accessible than the old overnight lab requirement.
Insurance Coverage and Appeals
This is where the OSA indication has the most practical value, and it is underused.
Many insurance plans exclude weight loss medications entirely as a category. That exclusion is why so many patients get denied Zepbound for obesity. But an FDA-approved indication for treating a distinct, serious medical condition is a different claim. Obstructive sleep apnea is not a cosmetic concern - it is a documented disorder with established cardiovascular consequences.
How to Approach It
- Get the sleep study documented. Your AHI number is the objective evidence the entire claim rests on. Make sure the report is in your medical record and available to your prescriber.
- Have your prescriber submit under the OSA indication, not the obesity indication, if you meet the criteria. This is a different prior authorization pathway.
- Document the full clinical picture. Prior CPAP trial and any adherence difficulty, comorbid hypertension or cardiovascular disease, daytime impairment, and the impact on your functioning all strengthen the case.
- Appeal a first denial. First denials are extremely common across this drug class and are frequently overturned. Do not treat a denial as final.
- Request a peer-to-peer review if the appeal is denied. Having your prescriber speak directly to the plan's medical reviewer is often more effective than paperwork.
If coverage still fails, self-pay routes exist. Zepbound single-dose vials through LillyDirect run $299-$449 per month depending on dose - see our full Zepbound cost breakdown. Medicare beneficiaries should check the Medicare GLP-1 Bridge program, where eligible participants pay a $50 monthly copay.
What to Expect on Treatment
Dosing for the OSA indication follows the standard Zepbound titration - starting at 2.5 mg weekly and escalating gradually. See our Zepbound dosage chart for the full schedule.
Realistic Timeline
- Weeks 1-8: Titration. Appetite suppression builds, weight loss begins. Do not expect measurable OSA improvement yet.
- Months 3-6: Meaningful weight loss accumulates. Some patients notice better sleep quality, less morning grogginess, and partners report reduced snoring.
- Months 6-12: The window in which a repeat sleep study becomes worthwhile. Trial outcomes were assessed at one year.
- Ongoing: Benefits persist while weight loss is maintained.
Side Effects
The side effect profile is the standard tirzepatide profile regardless of which indication you are treated under: nausea, vomiting, diarrhea, constipation, and reflux, concentrated during dose escalation. The boxed warning for thyroid C-cell tumors applies, along with risks of pancreatitis, gallbladder disease, and hypoglycemia when combined with insulin or sulfonylureas.
One consideration specific to this population: because the benefit comes from weight loss, preserving muscle mass matters. Losing lean mass alongside fat undermines the metabolic benefit and makes maintenance harder. See our GLP-1 muscle loss prevention guide.
Keep your sleep physician in the loop. Treating OSA with a medication prescribed for weight management can fall between specialties, with your prescriber managing the drug and your sleep physician managing the OSA. Make sure both know what the other is doing - particularly before any change to your PAP therapy.
Frequently Asked Questions
Is Zepbound FDA-approved for sleep apnea?
Yes. Zepbound (tirzepatide) is the first and only prescription medicine FDA-approved for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. Before this approval, no drug had ever been approved for OSA - the only treatments were mechanical, such as CPAP, oral appliances, positional therapy, or surgery.
How well does Zepbound work for sleep apnea?
In the Phase 3 SURMOUNT-OSA trials, tirzepatide reduced sleep apnea severity by up to nearly two-thirds, measured as a reduction in the apnea-hypopnea index. It also reduced body weight, hypoxic burden, hsCRP, and systolic blood pressure, and improved sleep-related patient-reported outcomes. At one year, reductions in AHI, nocturnal hypoxia, and overall OSA severity were significant compared with placebo.
Can I stop using CPAP if I start Zepbound?
Not on your own, and not right away. Weight loss on a GLP-1 is gradual, so your airway does not change in the weeks after starting. Stopping CPAP early means going back to untreated OSA throughout titration. Any decision to reduce or stop PAP therapy must come from your sleep physician and should be based on a repeat sleep study documenting improved AHI. SURMOUNT-OSA included participants using PAP therapy - the two can be used together.
Will insurance cover Zepbound for sleep apnea?
It is a meaningfully better claim than an obesity-only request, because many plans exclude weight loss drugs as a category while OSA is a distinct diagnosed medical condition with an FDA-approved indication. Coverage still varies. Have your prescriber submit under the OSA indication with your sleep study documented, include comorbidities and any CPAP adherence difficulty, and appeal a first denial - denials are frequently overturned.
My insurance denied Zepbound for sleep apnea. What should I do?
Appeal rather than accepting it. Make sure the submission included your sleep study with the objective AHI value, documentation of obesity, any prior CPAP trial and adherence difficulty, and related conditions such as hypertension or cardiovascular disease. If a written appeal fails, request a peer-to-peer review so your prescriber can speak directly with the plan's medical reviewer. If coverage ultimately fails, LillyDirect self-pay vials run $299-$449 per month.
Do I qualify if I have mild sleep apnea?
Not under this indication. The FDA approval covers moderate-to-severe OSA, meaning an AHI of 15 or higher on a sleep study, in adults with obesity. Mild OSA (AHI 5 to 14) falls outside it. You may still qualify for Zepbound under its separate obesity indication if you meet those criteria - that is a conversation to have with your prescriber.
Is Mounjaro approved for sleep apnea too?
Mounjaro contains the same active ingredient, tirzepatide, but it is approved for type 2 diabetes rather than obesity or OSA. The sleep apnea approval is specific to Zepbound. Same molecule, different approved indications and different branding - which matters for insurance coverage, since plans authorize by product and indication rather than by molecule.
How long until my sleep apnea improves?
Expect months, not weeks. The benefit follows weight loss, which builds gradually through titration. Many patients notice better sleep quality and reduced snoring by months three to six. Trial outcomes were assessed at one year, so that is the reasonable window for a repeat sleep study to document objective change. Do not change your CPAP use based on how you feel - use the sleep study.
What happens to my sleep apnea if I stop Zepbound?
Weight regain after stopping is well documented across the GLP-1 class, and since the OSA benefit comes from weight loss, sleep apnea severity would be expected to return as weight returns. This is an important consideration before starting: treatment is ongoing rather than a fixed course. Preserving muscle mass, maintaining protein intake, and continuing resistance training reduce how much weight comes back.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Zepbound (tirzepatide) is a prescription medication that should only be used under the supervision of a qualified healthcare provider. Obstructive sleep apnea is a serious medical condition requiring diagnosis by sleep study and management by a qualified clinician. Never stop or reduce CPAP or other PAP therapy without direction from your sleep physician - doing so can expose you to significant cardiovascular and daytime risk. Clinical trial figures represent group averages and do not predict individual results. Always review the full prescribing information for complete warnings and contraindications. HealthyPound may receive compensation from affiliate partners mentioned in this article. See our affiliate disclosure and full medical disclaimer for more information.